ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.1999G>C (p.Glu667Gln)

gnomAD frequency: 0.00001  dbSNP: rs1476749003
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001223250 SCV001395389 uncertain significance Bardet-Biedl syndrome 2022-08-20 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 667 of the BBS2 protein (p.Glu667Gln). This variant is present in population databases (no rsID available, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 951358). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002563034 SCV003760566 uncertain significance Inborn genetic diseases 2022-06-24 criteria provided, single submitter clinical testing The c.1999G>C (p.E667Q) alteration is located in exon 16 (coding exon 16) of the BBS2 gene. This alteration results from a G to C substitution at nucleotide position 1999, causing the glutamic acid (E) at amino acid position 667 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Preventiongenetics, part of Exact Sciences RCV003398966 SCV004118769 uncertain significance BBS2-related condition 2023-09-11 criteria provided, single submitter clinical testing The BBS2 c.1999G>C variant is predicted to result in the amino acid substitution p.Glu667Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-56519562-C-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
Natera, Inc. RCV001828779 SCV002089254 uncertain significance Bardet-Biedl syndrome 2 2021-07-06 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.